A Commercial Due Diligence for a Private Equity Buyer
A private equity buyer does not buy a company because last year looked good. It buys a future cash-flow story - and commercial due diligence is the stress test that asks, “Will the market, customers and competitors allow this story to come true?”
The trap is subtle: financial due diligence checks whether the numbers are reliable; commercial due diligence checks whether the numbers are repeatable, defensible and growable.
- Commercial due diligence validates whether a target company can achieve the revenue, margin and market-share assumptions behind a PE deal.
- The core question is: Is this an attractive market, and does this company have the right to win?
- A strong CDD covers five lenses: market, customers, competition, business model, and value creation plan.
- CDD is not only upside validation; the best work identifies downside risks, red flags and management over-optimism.
- For PE buyers, CDD directly feeds the investment committee memo, valuation model, debt capacity, 100-day plan and exit thesis.
- Key metrics include revenue CAGR, gross margin, customer concentration, retention, LTV/CAC and downside-case EBITDA impact.
- Interview answers should move from market attractiveness to competitive position to value creation - not jump straight to “the market is growing.”
Big Picture - What CDD Actually Proves
Commercial due diligence is the buyer’s reality check before committing capital. It asks whether the target’s growth plan survives contact with customers, competitors, pricing pressure, channel constraints and regulation.
In a PE deal, the commercial diligence output is not an academic market report. It must answer a capital-allocation question: Can this asset generate the growth, margin expansion and exit story required for the fund’s return target?
Core Explanation - The Five-Lens CDD Framework
A good CDD has a simple spine: start with the market, test the company’s position inside that market, then pressure-test the value creation plan. If any of these breaks, the valuation must change.
1. Market Attractiveness
This lens asks whether the target is playing in a market large and healthy enough to support the deal thesis. The team estimates total addressable market, serviceable market, growth rate, cyclicality, regulation, substitution risk and demand drivers.
For a stronger answer, separate market growth from capturable growth. A market may be expanding, but the target may be stuck in low-growth geographies, weak channels or price-sensitive segments.
2. Customer Quality
Customer diligence tests whether revenue is sticky or fragile. In B2B deals, this often includes customer interviews, churn analysis, wallet-share analysis, contract review and switching-cost assessment. In consumer deals, it may include brand perception, repeat purchase, pricing elasticity and channel feedback.
3. Competitive Position
This lens asks why the company should win against rivals. The answer may come from brand, distribution, cost advantage, technology, regulatory approvals, physician network, location density or customer lock-in. If this section feels weak, revise Competitive Landscape & Barriers to Entry before your interview.
4. Business Model and Unit Economics
Commercially attractive companies convert growth into cash. CDD therefore tests gross margin, contribution margin, sales productivity, capex intensity, working-capital drag, utilisation and operating leverage. A high-growth target with poor unit economics may still destroy value.
5. Value Creation Plan
PE buyers need more than “this is a good company.” They need a credible plan to create value during the holding period: pricing improvement, cross-sell, new geographies, channel expansion, operational efficiency, bolt-on acquisitions or digital sales. If the value plan depends on inorganic expansion, the team should also understand Entry Modes: Organic, Partnership, Joint Venture or Acquisition.
Key Metrics to Track in a CDD
Metrics vary by sector, but a PE diligence team usually wants measures that connect market demand to cash-flow quality. Treat the “good number” below as directional - always benchmark against the target’s sector and peer set.
Worked Example - How CDD Feeds the Deal Model
Assume a PE fund is evaluating a hypothetical specialty education business with ₹100 crore revenue and ₹20 crore EBITDA today. Management claims revenue can grow 20 percent annually for three years.
The interview insight: CDD does not sit outside valuation. It changes the assumptions inside the model - growth, margin, capex, churn, pricing, exit multiple and downside risk.
Definitions You Should Be Able to Say Cleanly
- Commercial due diligence: An independent assessment of a target’s market, customers, competition and growth plan before an investment decision.
- Investment thesis: The buyer’s reason for believing the target can create attractive risk-adjusted returns.
- Right to win: The company-specific advantage that lets a target outperform competitors in its chosen market.
- Red flag: A material risk that can change valuation, deal structure, conditions, or the decision to invest.
- Value creation plan: The practical set of actions through which the buyer expects to improve performance after acquisition.
Case Study - Temasek and Manipal Health
Temasek’s majority investment in Manipal Health is a useful Indian example of how a buyer would test healthcare demand, competitive position and scalable value creation before committing capital.
Manipal Health operates in a sector with powerful demand drivers: rising healthcare awareness, urbanisation, insurance penetration and preference for organised hospital networks. But a PE-style commercial diligence would not stop at “Indian healthcare is growing.” That would be too shallow.
The more important question is whether the platform has a defensible right to win. For a hospital chain, the primary driver is usually trusted clinical delivery at scale. Supporting drivers include doctor retention, specialty depth, bed utilisation, local brand trust, referral networks, payer relationships, expansion discipline and operating protocols across hospitals.
When Temasek announced its investment in Manipal Health, it was backing a scaled healthcare platform rather than a single hospital asset (Temasek, 2023). A CDD team would have tested whether that platform could keep growing without diluting clinical quality or overpaying for expansion.
The lesson is memorable: in healthcare CDD, market demand is only the starting point. The winning investment case depends on whether the buyer can scale trust, clinical talent and operating discipline together.
How AI Changes Commercial Due Diligence
AI is changing CDD by making outside-in analysis faster, broader and more evidence-rich. It does not replace judgement; it improves the speed at which a team can find patterns, contradictions and diligence questions.
Practical student workflow: load the target company’s annual report, two competitor reports and your case prompt into NotebookLM. Ask it to generate: “10 commercial diligence questions a PE investment committee would ask, grouped by market, customers, competition, economics and value creation.” Then practise answering those questions aloud using ChatGPT as a mock interviewer; this pairs well with Practising Cases With AI as a Mock Interviewer.
Interview Relevance
A private equity client is considering buying a regional hospital chain in India. How would you conduct commercial due diligence before advising whether to proceed?
In a PE CDD answer, keep saying what each finding means for the deal: price, risk, debt capacity, value creation plan or walk-away decision.
Common Mistake
The biggest mistake is giving a market-sizing answer and calling it commercial due diligence. That costs candidates because PE buyers do not invest in markets; they invest in companies with defensible economics. Fix: after market attractiveness, always test the target’s right to win, customer stickiness, unit economics and downside risks.